EDGC and Eutilex Jointly Develop Immune-Oncology Customized Anticancer Therapy

[Asia Economy Reporter Park Jihwan] Eone Diagnomics announced on the 28th that it has signed a business agreement with Eutilex, which develops T-cell therapies, CAR-T cell therapies, and immune-oncology antibody therapies, to develop immune-oncology treatment services through genome big data-based precision diagnostics.

The business agreement between the two companies includes collaborative research on genome analysis and immune-oncology pipelines, clinical research and development of precision immune-oncology pipelines, NGS-based genetic classification of cancer patients, and biomarker discovery.

Lee Seonghoon, EDGC CTO (Chief Technology Officer), stated, "By integrating cancer classification and diagnosis through genome big data analysis with Eutilex's immune-oncology treatments, we have taken a step closer to personalized precision treatment for cancer patients. Based on this agreement, we expect to apply our advanced cfDNA liquid biopsy early cancer diagnosis technology to immunotherapy, expanding its use not only for early cancer treatment but also for cancer prevention."

EDGC plans to proceed with the approval process from the Ministry of Food and Drug Safety next year for screening products that enable early stage 1 diagnosis of lung, breast, and colorectal cancers through blood tests (cfDNA liquid biopsy) during health checkups, as well as monitoring products that track cancer recurrence and progression. Along with Grail, recently acquired by Illumina in the U.S. for 9 trillion KRW, they are attempting the world's first commercialization.

This content was produced with the assistance of AI translation services.